Compare State Street SPDR S&P Biotech ETF (XBI) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs DENTSPLY SIRONA Inc — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.93, while DENTSPLY SIRONA Inc trades at $10.68 (market cap $2.19B). The key difference: DENTSPLY SIRONA Inc pays a 5.04% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, DENTSPLY SIRONA Inc nearer its low. Which is the better fit depends on your goals.
| XBI | XRAY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $169.55 | $14.68 |
52-Week Low | $93.43 | $9.64 |
Market Cap | — | $2.19B |
Enterprise Value | — | $4.26B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XRAY trades at $10.99, down 3.43% on the day, reflecting ongoing challenges amid a bearish technical signal. The company reported a Q2 2026 earnings beat but faces declining revenue and negative profitability, with a net income margin of -14.99%. Cash flow trends show volatility, and the debt-to-asset ratio has worsened to 42.88% in 2025. Recent news highlights margin pressure and a class-action lawsuit inquiry, clouding the near-term outlook despite some institutional buying interest.
The investment outlook is cautious. While the stock trades below the consensus price target of $12.50, persistent net losses, high debt, and competitive pressures pose significant risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited upside until the company demonstrates sustained operational improvement and revenue stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
